Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Reaffirmed as “Underperform” by Needham & Company LLC

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “underperform” rating reaffirmed by analysts at Needham & Company LLC in a note issued to investors on Monday, Benzinga reports.

Other research analysts also recently issued research reports about the company. Weiss Ratings downgraded Sarepta Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 24th. Wolfe Research upgraded Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 target price for the company in a report on Thursday, July 9th. Zacks Research raised Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Wall Street Zen cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, HC Wainwright reissued a “buy” rating on shares of Sarepta Therapeutics in a research note on Tuesday, July 28th. Eight equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and six have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $24.07.

Sarepta Therapeutics Stock Down 0.9%

Shares of NASDAQ SRPT opened at $18.64 on Monday. The stock has a market capitalization of $1.97 billion, a P/E ratio of -6.43, a PEG ratio of 0.27 and a beta of 0.27. Sarepta Therapeutics has a one year low of $14.68 and a one year high of $25.32. The firm’s 50 day simple moving average is $18.87 and its two-hundred day simple moving average is $18.79. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.42 and a quick ratio of 2.62.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.42. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The company had revenue of $401.25 million during the quarter, compared to analysts’ expectations of $366.39 million. During the same quarter in the prior year, the company earned $2.02 EPS. The firm’s revenue was down 34.3% on a year-over-year basis. As a group, analysts expect that Sarepta Therapeutics will post 3.53 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Tidal Investments LLC purchased a new stake in Sarepta Therapeutics in the 2nd quarter worth approximately $183,000. Baird Financial Group Inc. increased its stake in shares of Sarepta Therapeutics by 7.6% during the second quarter. Baird Financial Group Inc. now owns 12,805 shares of the biotechnology company’s stock valued at $230,000 after buying an additional 901 shares during the period. Nykredit A S purchased a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $43,000. Corient Private Wealth LP raised its holdings in shares of Sarepta Therapeutics by 273.4% during the second quarter. Corient Private Wealth LP now owns 36,712 shares of the biotechnology company’s stock valued at $660,000 after acquiring an additional 26,880 shares in the last quarter. Finally, Amundi bought a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $350,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. Its research platforms include RNA-based technologies, gene therapy and gene-editing approaches designed to address the underlying causes of genetic disorders.

The company’s primary commercial focus has been Duchenne muscular dystrophy (DMD). Sarepta markets Exondys 51, Vyondys 53 and Amondys 45, exon-skipping therapies for eligible patients with specific genetic mutations, as well as Elevidys, a gene therapy developed to treat certain patients with DMD.